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ARTICLE OPEN
Humoral protection against mosquito bite-transmitted
Plasmodium falciparum infection in humanized mice
Brandon K. Sack1, Sebastian A. Mikolajczak1, Matthew Fishbaugher1, Ashley M. Vaughan1, Erika L. Flannery1, Thao Nguyen1, Will Betz1,
Mary Jane Navarro1, Lander Foquet1, Ryan W. J. Steel1, Zachary P. Billman2, Sean C. Murphy1,2, Stephen L. Hoffman3,
Sumana Chakravarty3, B. Kim Lee Sim3, Marije Behet4, Isaie J. Reuling4, Jona Walk4, Anja Scholzen4, Robert W. Sauerwein4,
Andrew S. Ishizuka5, Barbara Flynn5, Robert A. Seder5 and Stefan H. I. Kappe1,6
A malaria vaccine that prevents infection will be an important new tool in continued efforts of malaria elimination, and such
vaccines are under intense development for the major human malaria parasite Plasmodium falciparum (Pf). Antibodies elicited by
vaccines can block the initial phases of parasite infection when sporozoites are deposited into the skin by mosquito bite and then
target the liver for further development. However, there are currently no standardized in vivo preclinical models that can measure
the inhibitory activity of antibody speciﬁcities against Pf sporozoite infection via mosquito bite. Here, we use human liver-chimeric
mice as a challenge model to assess prevention of natural Pf sporozoite infection by antibodies. We demonstrate that these mice
are consistently infected with Pf by mosquito bite and that this challenge can be combined with passive transfer of either
monoclonal antibodies or polyclonal human IgG from immune serum to measure antibody-mediated blocking of parasite infection
using bioluminescent imaging. This methodology is useful to down-select functional antibodies and to investigate mechanisms or
immune correlates of protection in clinical trials, thereby informing rational vaccine optimization.
npj Vaccines  (2017) 2:27 ; doi:10.1038/s41541-017-0028-2
INTRODUCTION
Despite considerable effort and substantial progress in reducing
the malaria burden in many countries over the past decade, more
than 200 million people still suffered from this parasitic disease in
2015, resulting in over 400,000 deaths due in large part to
infection with Plasmodium falciparum (Pf) (WHO 2015). A vaccine
capable of preventing malaria infection would prevent disease,
death and onward parasite transmission and as such would
constitute a critical tool in disease reduction as well as parasite
eradication. However, all licensed vaccines to date have targeted
viruses and bacteria, and although malaria vaccine development
has seen some recent progress, a vaccine capable of delivering
high levels of durable protection from Plasmodium parasites has
yet to be developed.
During their complex life cycle within the mammalian host,
malaria parasites present multiple targets for antibody-mediated
interference with infection, providing a strong rationale that
antibody-based vaccines could effectively interrupt the parasite
transmission cycle and prevent disease and death. Whole
attenuated parasite vaccine candidates and subunit vaccine
candidates can both elicit protective antibody responses capable
of neutralizing or destroying the parasite during infection.1–8
Attenuated parasites stimulate a broad antibody and T cell-
mediated adaptive immune response against numerous parasite
antigens. Subunit vaccines constitute a narrower approach where
recombinant or vectored parasite antigen(s) are formulated with
an immune-stimulatory adjuvant to elicit an antigen-speciﬁc
response.
Antibodies can block Plasmodium parasite infection in the skin
immediately after transmission, which occurs when an infected
Anopheles mosquito injects tens to a few hundred sporozoite
stages during a bite. Sporozoites are highly motile and traverse
multiple cell types in search of a blood vessel, which gains them
access to the blood circulation. In rodent models of malaria, it was
shown that antibodies targeting the sporozoite can effectively
prevent passage of the sporozoite to the liver by reducing the
number of sporozoites ejected from the mosquito proboscis and
also immobilizing the sporozoite in the dermis, thereby prevent-
ing their access to the circulation.9,10 Sporozoite motility and cell
traversal are processes that require unique secreted and
membrane-anchored proteins, which might be targeted with
antibodies to prevent access to the blood circulation.11,12 Once in
the circulation, sporozoites are rapidly transported to the liver
where they again traverse multiple cell types as they cross the
liver sinusoidal barrier and then infect a suitable hepatocyte.
Leaving the circulation to enter the liver parenchyma also
presents an opportunity for antibody-mediated prevention of
infection as sporozoites are exposed to circulating antibodies that
could target multiple sporozoite proteins involved in cell traversal
and invasion, potentially preventing hepatocyte infection and in
consequence, parasite replication in the liver. This in turn prevents
the release of exo-erythrocytic merozoites and the establishment
of a blood stage infection and its associated mortality and
morbidity.13
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The sporozoite and liver stages, collectively called the pre-
erythrocytic (PE) stages of the parasite, are asymptomatic and are
therefore attractive vaccine targets. Preventing the PE stages of
infection will prevent all disease and the establishment of
circulating sexual stage parasite populations that are transmis-
sible. Indeed, endeavors are underway to identify new antibody
targets for PE stages based on comprehensive sporozoite surface
proteome and secretome data and a more in depth molecular
understanding of the biological processes of parasite cell traversal
and hepatocyte invasion.14,15 However, preclinical laboratory
assays for assessing infection-inhibiting antibodies are extremely
limited. Traditionally, rodent malaria models have been used for
active immunization or for passive transfer of polyclonal or
monoclonal antibodies followed by sporozoite challenge. How-
ever, there is signiﬁcant evolutionary divergence between the
malaria parasite species that infect rodents and humans, limiting
the rodent malaria models as predictive preclinical experimental
systems. Transgenic rodent malaria parasites carrying individual Pf
antigens of interest have been created as bridging tools, but these
are limited in the type and number of antigens that can be
assessed.16–18 Thus, preclinical in vivo models that directly assess
antibody efﬁcacy against Pf challenge could be extremely helpful
to inform which antigen candidates are to be advanced to clinical
trials using controlled human malaria infection (CHMI).19 Without
robust preclinical evidence for protective efﬁcacy of subunit
vaccine candidates against Pf challenge, CHMI trials have resulted
in numerous vaccine candidate failures in the past.20–25 Although
in vitro assays to evaluate antibody-mediated protection against
Pf sporozoite infection have been established using monocultures
of hepatoma cells or primary human hepatocytes26 they do not
recapitulate the sporozoites infection route from the skin to the
liver and therefore cannot capture antibody activities that block
the parasite prior to hepatocyte infection.13,27,28
A bridge between preclinical in vitro assays and human CHMI
trials could be built with liver-humanized mice, which fully support
Pf PE infection.29,30 Measurement of parasite liver stage burden
can then be used to assess passively transferred antibody
efﬁcacy.6,31,32 We have previously shown that these liver-
chimeric humanized mice (referred to as FRG huHep mice), when
challenged with a luciferase-expressing Pf parasite can be used to
detect antibody-mediated reduction in liver infection by biolumi-
nescent imaging.2,29,33,34 Here, we use FRG huHep mice to develop
a robust platform to evaluate the protective efﬁcacy of antibodies
against natural Pf infection. We demonstrate that this model can
differentiate monoclonal antibodies (mAbs) of varying infection-
blocking activity and measure the infection-blocking activity of
polyclonal immune IgG from human volunteers immunized with
whole sporozoites. We also have adapted this model to measure
antibody-mediated sterile protection using a physiologically
relevant challenge dose. Importantly, mosquito bite challenge of
FRG huHep mice discriminated antibody performance that was
superior to in vitro assays, indicating the importance of using the
natural Pf parasite infection route when assessing interventions
against PE infection.
RESULTS
Pf liver infection following mosquito bite challenge
To determine antibody inhibitory function in vivo, we used the
natural mosquito bite route of infection as opposed to intravenous
(iv) injection of sporozoites, which has been used in the past but
bypasses the skin stage and is less sensitive to antibody-mediated
inhibition.33,35 However, mosquito bite infection is challenging to
standardize, as it is difﬁcult to control the precise sporozoite dose.
Thus, we ﬁrst asked if FRG huHep mouse infection with Pf
parasites36 by mosquito bite yields a parasite stage liver burden of
sufﬁcient magnitude and consistency. We thus challenged FRG
huHep mice with 25, 50, 75 or 100 Pf GFP_luc-infected mosquitoes
each for 10 min. Liver stage burden was then quantiﬁed via
bioluminescence on days 4–6 after infection (Fig. 1a). All mice had
detectable liver infection on day 4 that increased on days 5 and 6
consistent with parasite liver stage growth over time (Fig. 1b). On
day 6, all infections were statistically similar except the 25-bite
group, which was signiﬁcantly lower than both the 100 and 75
bite groups (p = 0.0021 and 0.0427, respectively, by two-way
analysis of variance (ANOVA) for each day, Fig. 1b and Table 1).
Given that 50 infected mosquito bites resulted in similar liver
stage burden when compared to 75 and 100 mosquito bites
(Table 1), we chose 50 bites as a standard dose for all further
experiments. This dose proved to be consistent in terms of
achieving a high magnitude of liver stage infection in all mice with
a reasonable degree of variability that allowed us to detect
antibody-mediated reductions in parasite liver infection in
subsequent experiments (Supplementary Fig. S1).
Noninvasive quantitation of Pf parasite burden in the liver following
passive antibody transfer. Bioluminescent imaging is a rapid and
non-invasive method for assessing parasite liver stage burden.
However, our initial experiments using mosquito bite infection
showed variability within each experiment, which could preclude
assessment of small changes in parasite burden such as those
Fig. 1 FRG huHep mice are susceptible to P. falciparum infection by
mosquito bite and parasite liver stage burden can be measured
noninvasively by bioluminescent imaging. a Overall schematic of
passive transfer and mosquito bite infection of FRG huHep mice.
Mice are administered antibody 16–24 h prior to infection with Pf
GFP_luc-infected mosquitoes followed by subsequent assessment
of liver stage burden by bioluminescence at 4–6 days post infection.
b Mice were exposed to the bites of 25, 50, 75 or 100 mosquitoes
and tracked for liver stage burden from days 4–6. Individual mice are
shown as data points with the mean for each group shown by the
color-corresponding connecting line
Table 1. Mean liver burden and variation at day 6 post infection
Mosquito
bites
n Mean liver
burden (p/s)
SD SEM Coefﬁcient
of variation
25 10 0.839 × 107 0.686 × 107 0.217 × 107 81.7%
50 10 1.74 × 107 1.451 × 107 0.459 × 107 83.4%
75 10 1.91 × 107 1.623 × 107 0.514 × 107 85%
100 10 2.31 × 107 1.852 × 107 0.586 × 107 80.2%
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caused by moderate inhibition of infection with antibodies. Thus,
we compared bioluminescent imaging and quantitative reverse
transcriptase PCR (qRT-PCR) using parasite-speciﬁc probes to
detect antibody-mediated reduction of liver infection. The latter
method involves RNA extraction from infected liver and detection
of parasite RNA by qRT-PCR.6,31 We compared these two methods
by assessing the effect of passive transfer of 5, 50 and 150 μg of an
anti-circumsporozoite protein (CSP) mAb on liver stage burden. A
schematic example of sampling infected livers by both methods is
shown in Fig. 2a. Six days after mosquito bite infection, liver stage
burden was detectable in all mock-treated mice (mice receiving an
equivalent dose of non-speciﬁc IgG) by both bioluminescent
imaging and qRT-PCR (Fig. 2b) with considerable variability in
both (coefﬁcient of variance of 296 and 56% for qRT-PCR and
bioluminescence, respectively). Both methods detected a signiﬁ-
cant reduction of liver stage burden following passive transfer of
150 μg of anti-CSP mAb with 3/5 mice having detectable liver
burden by qRT-PCR and 5/5 by bioluminescent imaging (Fig. 2b).
Whereas bioluminescent imaging could distinguish differences in
liver stage parasite burden in mice given 5 and 50 μg of mAb, qRT-
PCR could not, due to the large variability in signal (Fig. 2b). These
results indicate that both bioluminescent imaging and this
method of qRT-PCR detect relatively large differences in liver
stage burden but that the former may be more useful in
discriminating moderate reductions in liver stage burden.
FRG huHep mouse challenge to assess functional activity of mAbs
We next tested whether the FRG huHep/Pf GFP_luc challenge
model could be used to measure differences in prevention of liver
infection by distinct mAbs that target the same sporozoite
antigen. To this end, we passively transferred three different
mAbs of mouse origin that recognize the NANP repeat region of Pf
CSP at 150 μg/mouse: mAb clone 2A10 (murine isotype IgG2b),
mAb1 (murine isotype IgG1) and mAb2 (murine isotype IgG1).
mAb 2A10 reduced liver infection to 51% of mock-treated mice
while mAb1 and mAb2 reduced liver infection signiﬁcantly to 10
and 31% of mock-treated mice, respectively (Fig. 3). To determine
if the isotype of the mAb inﬂuenced antibody function, we also
tested variants of mAb1 and mAb2 with isotypes known to better
mediate Fc-dependent functions.37 Both mAb1-IgG3 and mAb2-
IgG2a performed similarly to their IgG1isotype counterparts,
indicating that antibody isotype was not a factor for in vivo
performance in these experiments (Fig. 3). The results with these
mAbs were consistent between replicate experiments (indicated
by different colors in Fig. 3) despite differences in liver stage
burden of mock groups (Supplementary Fig. S1). Importantly, the
hierarchy in infection-inhibitory activity of each mAb, where
mAb1 >mAb2>mAb 2A10, was not observed in an in vitro
inhibition of sporozoite traversal and invasion (ISTI) assay where all
mAbs performed similarly (Supplementary Fig. S2). This indicates
that the assessment of antibody function in vitro may not fully
reveal the inhibitory activity on sprozoite infection observed
in vivo.
To increase the utility of the FRG huHep challenge model, we
assessed whether mAbs of human origin can also be tested (i.e.,
derived from B cells from vaccinated volunteers). mAbs with
human Fc regions set up a species mismatch between the
antibody Fc region and the murine Fc receptor and this could
diminish the contribution of Fc-dependent effector functions and
obscure protection status.38 However, we observed that passive
transfer of a version of mAb1 containing a human IgG3 (huIgG3)
Fc region yielded similar results when compared to its murine
counterparts (Fig. 3). Taken together, these data indicate that the
FRG huHep/Pf GFP_luc challenge model discriminates distinct
mAb blocking activities and enables functional assessment of
mAbs of various Fc isotypes of both murine and human origin.
Inhibitory activity of polyclonal IgG from whole sporozoite-
immunized volunteers
We next assessed the inhibitory activity of human polyclonal
antibodies collected after immunization of volunteers with live-
attenuated Pf sporozoites.
Fig. 2 Bioluminescent imaging is as accurate as qRT-PCR for assessment of liver stage burden. a Schematic representing liver sampling with
qRT-PCR (upper panels) and bioluminescence (lower panels). Sampling of livers with biopsy punch for qRT-PCR is indicated by 12 circles
where green circles indicate samples in which parasite RNA would be detected and red those which would be negative in mice with high liver
burden (left) and low liver burden (right). In contrast, assessment of liver burden by bioluminescence is shown in the bottom panels and
indicates a representative region of interest that can capture the entire liver. b FRG huHep mice were administered indicated doses of anti-CSP
mAb 2A10 or 150 μg of non-speciﬁc murine IgG (mock). The following day, mice were infected with 50 Pf GFP_luc mosquito bites and assessed
for liver burden at day 6 by bioluminescent imaging. Immediately following imaging, mice were sacriﬁced and 12 samples from each liver
were collected and combined for RNA isolation and quantitation of liver burden by qRT-PCR. Liver burden by both qRT-PCR (left y-axis) and
bioluminescence (right y-axis) are shown with each data point representing the mean liver burden from the 12 liver sections from one mouse
for qRT-PCR and the total ﬂux for each mouse measured by bioluminescence
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Immune serum or plasma from malaria vaccine trials is often
limited and in previous studies using passive transfer of huIgG, the
dose of IgG was dictated by sample availability.2,34 Thus, to ﬁrst
characterize the range of huIgG inhibitory activity in the FRG
huHep/Pf GFP_luc challenge model, polyclonal huIgG pooled from
samples collected from whole sporozoite-immunized
volunteers2,34 was passively transferred at 0.5, 2, 4, 8 and 16mg/
mouse. We detected signiﬁcant reductions in parasite liver stage
burden as compared to mice receiving equivalent doses of pre-
immune huIgG at doses as low as 4 mg/mouse (Fig. 4a). The serum
levels of huIgG in mice receiving these inhibitory doses at the time
of challenge were an average of 1.5, 4.5 and 8.3 mg/mL for doses
of 4, 8 and 16mg/mouse, respectively (Fig. 4b). Together, these
data indicate that a range of huIgG concentrations can be used to
determine antibody functionality in the FRG huHep/Pf GFP_luc
challenge model and that a dose of 16 mg/mouse can closely
recapitulate the concentration of huIgG observed in human
serum.39
We next used huIgG isolated from volunteers immunized with
whole sporozoites and subsequently challenged by CHMI. The ﬁrst
set of huIgG was derived from volunteers intravenously immu-
nized with four doses of 2.7 × 105 puriﬁed, cryopreserved
irradiated sporozoites (PfSPZ).2 CHMI 6 months after ﬁnal
immunization demonstrated protection in 6/11 volunteers.2 We
obtained sufﬁcient sample to transfer 8 mg of huIgG/FRG huHep
mouse (n = 3–10 mice/volunteer) taken at the time of CHMI from
ﬁve protected and four non-protected volunteers. Control FRG
huHep mice received 8mg/mouse of pooled pre-immune huIgG
from all nine volunteers and all mice were challenged by 50 Pf
GFP_luc-infected mosquito bites. Compared to mice receiving
pooled pre-immune huIgG, the immune huIgG from 4/5 protected
volunteers signiﬁcantly reduced parasite liver infection while
immune huIgG from only 1/4 non-protected volunteers demon-
strated signiﬁcant reduction of liver infection (Fig. 5a). When
grouped together, mice receiving immune huIgG from protected
volunteers showed signiﬁcantly reduced parasite liver burden
(38% of pre-immune) as compared to mice receiving huIgG from
non-protected volunteers, which only had a non-signiﬁcant (66.6%
of pre-immune) reduction in liver stage burden (Fig. 5b). However,
this correlation was not evident on an individual volunteer basis as
the mean parasite liver burden of mice receiving huIgG from a
single volunteer (i.e., 1 mean/volunteer) was not statistically lower
for individuals in the protected group as compared to the non-
protected group despite a lower numerical value (Fig. 5c). Thus,
antibody inhibitory function in vivo was not a clear correlate of
protection for volunteers in this study. Regardless, the observed
trends in differences between protected versus non-protected
huIgG were not detected using an in vitro ISTI assay where IgG
from 3/3 non-protected volunteers tested signiﬁcantly inhibited
Fig. 4 Human polyclonal IgG can be used over a wide dose range in the FRG huHep/Pf GFP_luc challenge model. FRG huHep mice (n= 4–5/
group) received indicated doses of pooled pre-immune or immune polyclonal IgG at indicated doses. a Parasite liver stage burden was
measured at day 6 post 50 mosquito bite challenge and the liver stage burden of each mouse receiving huIgG from immunized volunteers
(Immune) was normalized to the average of the dose-matched huIgG from the pre-immunized volunteers (Pre-immune). Mean ± SEM is
plotted with comparisons between pre-immune and immune liver stage burdens carried out by Mann–Whitney U test. Asterisks indicate a
signiﬁcant difference between means where * is p< 0.05 and ** is p≤ 0.01. b Mice were bled immediately prior to challenge and serum was
collected for measurement of circulating huIgG by ELISA. Concentration is depicted on the y-axis with mean± SEM plotted for each group.
Included are groups of mice that received a murine anti-CSP mAb or PBS (negative controls, n= 2 and 6, respectively)
Fig. 3 Monoclonal Abs of multiple Fc isotypes and species can be
assessed in the FRG huHep/Pf GFP_luc challenge model. FRG huHep
mice received 150 μg/mouse of non-speciﬁc IgG, mAb 2A10 or two
novel anti-CSP mAb prior to mosquito bite infection and measure-
ment of liver stage burden. Species and isotype are indicated for
each mAb (e.g., mIgG1 for “murine IgG1” and “hu” for human). Data
were collected over four independent experiments with 1–3
experiments/mAb and 4–5 mice/group/experiment. Each data point
represents one mouse and mice within the same experiment are
labeled in the same color. Bars indicate mean± SEM with numbers
above each bar indicating the mean % of mock for that group.
Asterisks indicate statistical signiﬁcance in one-way ANOVA compar-
ing to mock-injected mice in the same independent experiments.
Individual comparisons between mAb of the same speciﬁcity but
different Fc isotypes/species are indicated with lines. ** is 0.01> p>
0.001, **** is p< 0.0001
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sporozoite invasion whereas IgG from only 3/5 protected
volunteers showed signiﬁcant inhibition of invasion (Supplemen-
tary Fig. S3A, B). Comparing in vitro inhibition of either cell
traversal or invasion to FRG huHep/Pf GFP_luc challenge data also
yielded no correlation between the two assays suggesting a
fundamental difference between sporozoite infection in the
in vitro assay and the in vivo assay (Supplementary Fig. S3C).
Finally, the in vivo data included a replicate with a subset of
immune huIgG to assess the reproducibility. We found results to
be consistent between experiments using different batches of Pf
GFP_luc-infected infected mosquitoes (Supplementary Fig. S4).
We next tested a set of huIgG from volunteers immunized by
the chloroquine prophylaxis with sporozoites (CPS) protocol.40 CPS
administers fully infectious sporozoites by mosquito bite to
volunteers that concurrently receive chloroquine, which leads to
complete liver stage development, release of exo-erythrocytic
merozoites and subsequent elimination of the ﬁrst cycle of blood
stage parasites. CPS has proven to be highly efﬁcacious,6,40,41 and
in this trial protected 5/8 volunteers from CHMI. Due to sample
limitations, we only transferred 5mg huIgG into each FRG huHep
mouse (3–5 mice/volunteer). Controls received either pre-immune
huIgG or only phosphate-buffered saline (PBS). There was no
signiﬁcant difference between pre-immune huIgG and PBS-
treated mice (Supplementary Fig. S5A). When compared to mice
receiving pre-immune huIgG, immune huIgG from 1/5 protected
volunteers signiﬁcantly reduced parasite liver stage burden with
another non-signiﬁcantly reducing liver stage burden to 36% of
control (Fig. 6a). In contrast, immune huIgG from none of the three
non-protected volunteers reduced parasite liver burden (Fig. 6a).
Grouping of mice based on those that received immune huIgG
from either protected or non-protected volunteers, as in Fig. 5b,
revealed that the parasite liver stage burden of mice receiving
“protected” immune huIgG was lower (68% of PBS) than mice
receiving either pre-immune huIgG (148% of PBS) or “non-
protected” immune huIgG (160% of PBS, Fig. 6b). Grouping the
mean parasite liver stage burdens of mice receiving huIgG from a
single volunteer (one mean/volunteer) as in Fig. 5c revealed a
lower average parasite liver stage burden after passive transfer of
“protected” huIgG (72% of PBS) as compared to “non-protected”
huIgG (166%, Fig. 6c). Again, these in vivo results were not
predicted by the in vitro ISTI assay (Supplementary Fig. S5B).
Although limited by small sample sizes, these data together
demonstrate that the FRG huHep/Pf GFP_luc challenge model can
be used to distinguish functional from non-functional polyclonal
antibodies derived from volunteers vaccinated with whole
sporozoites. The trends we observed also suggest that this model
could be used to establish correlates of protection based on the
in vivo function of antibodies but will likely require analysis of
vaccine trials with larger cohort sizes.
The ultimate goal of malaria vaccination is sterile protection, i.e.,
the complete prevention of parasite egress from the liver and
subsequent onset of blood stage infection. Measuring reduction of
liver stage burden as shown here does not directly assess sterile
protection. We addressed this by performing passive mAb transfer
followed by challenge with ﬁve Pf NF54-infected mosquito bites
(the number of infected mosquitoes used for CHMI) and used the
transition to blood stage infection instead of parasite liver burden
as an endpoint of protection. At this low challenge dose,
reductions in liver infection cannot be studied by bioluminescent
imaging as the luminescence derived from this smaller infection is
at the limit of detection without antibody treatment. Mice in this
experiment were given 150, 50 or 15μg/mouse of mAb 2A10 the
day prior to challenge and injected with human red blood cells on
day 6.5 to allow parasite transition into the blood. The following
day (day 7), peripheral blood was taken and parasite density
measured by Plasmodium 18S rRNA qRT-PCR. None of the mice
treated with non-speciﬁc mIgG were protected as all mice had
detectable blood stage infection. However, in mice that received
150 μg mAb/mouse, a dose which reduced liver burden by 49%
after 50 mosquito bite challenge, 2/5 were sterilely protected from
the 5 bite challenge. Reduction in dose to 50 μg/mouse also
resulted in 2/5 mice protected while an even lower dose of 15μg
failed to show any protection (Fig. 7a). Parasite densitites in
infected mice that received 150 μg of mAb were 52-fold lower
than mIgG-treated mice (p < 0.05). Unprotected mice in the 50 μg
dose group and the 15μg group had non-signiﬁcant reductions in
parasite densitites by 45-fold and 4.8-fold, respectively. We also
determined the circulating mAb levels at the time of challenge in
Fig. 5 The FRG huHep/Pf GFP_luc challenge model can distinguish functional from non-functional antibodies from human volunteers. FRG
huHep mice were administered 8mg/mouse of IgG from volunteers 6 months after immunization with four doses of 2.7 × 105 irradiated
sporozoites (PfSPZ) and immediately prior to challenge by infectious mosquito bite. Mice were then infected by bite of 50 Pf GFP_luc-infected
mosquitos and liver stage burden assessed at day 6 post infection. Data shown are a combination of two independent experiments as
delineated in Figure S4 and expressed as a percent of pre-immune parasite liver burden (% of pre-immune). a Liver stage burdens of mice
(n= 3–10/volunteer) receiving post-immunization IgG were normalized to mice receiving pooled pre-immune IgG (n= 13). Data points are
shown with bars as mean ± SEM for each volunteer grouped by protection status. Asterisks indicate signiﬁcant differences from the pre-
immune group as measured by one-way ANOVA with Kruskal–Wallis post-test. b Data in a arranged such that each mouse is plotted as a single
data point and grouped according to their treatment, pre-immune huIgG, immune huIgG from a CHMI protected volunteer or immune huIgG
from a non-protected CHMI volunteer. Above each group is the mean % of pre-immune as well as asterisks indicating a signiﬁcant difference
from the mean of the pre-immune group as measured by one-way ANOVA with Kruskal-Wallis post-test. An additional Mann–Whitney test
comparing the means of protected and non-protected is indicated by bar and resulting p value. c Data represented as one mean per
volunteer with Mann-Whitney test used to determine if the mean % of mock are different. For all comparisons ** is p≤ 0.01, *** is p≤ 0.001
and **** is p≤ 0.0001
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these mice to be an average of 38, 9.6 and 4.1 μg/mL in the 150,
50 and 15 μg/mouse groups, respectively. Thus, in addition to
determining reductions in parasite liver burden following passive
transfer, FRG-huHep mice can be used to measure sterile
protection using a natural mosquito bite challenge that is
equivalent to CHMI using a qRT-PCR endpoint assay also used in
CHMI studies.34,42,43
DISCUSSION
The malaria vaccine candidate RTS,S containing the imunodomi-
nant protein on the sporozoite surface, PfCSP, has undergone
extensive clinical testing. It has achieved modest protection in
phase III trials that correlate with anti-CSP-antibody titers and with
CD4+ T cell responses3,4—evidence that antibodies against
sporozoite antigens can afford protection against malaria in
humans. This is corroborated by decades of studies in rodent
malaria models using both active immunization and passive
transfer of mAbs that demonstrate infection-blocking
activity.9,33,35,44–47 Furthermore, clinical trials using immunization
with live-attenuated sporozoites elicit anti-sporozoite antibodies
that inhibit sporozoite infection in vitro and in vivo, and in some
cases these antibody titers and in vitro function correlate with
protection.1,2,6,48 Targeting the liver stages of parasite infection
Fig. 6 Antibody function in the FRG huHep/Pf GFP_luc challenge model can be used as a correlate of protection. FRG huHep were
administered 5mg/mouse of IgG collected from volunteers either before (“Pre-Imm”) or 2 weeks after three immunizations with 15 Pf-infected
mosquito bites under chloroquine prophylaxis. Mice were infected by the bite of 50 Pf GFP_luc-infected mosquitos and liver burden assessed
at day 6 post infection. a Parasite liver stage burdens of mice (n= 3–5/volunteer) receiving pooled pre-immunization or individual post-
immunization huIgG were normalized to mice receiving an equivalent volume of PBS (% of PBS). Data points are shown with bars as mean ±
SEM for each volunteer and grouped by protection status. Asterisks indicate signiﬁcant differences from the pre-immune group as measured
by one-way ANOVA with Kruskal–Wallis post-test. b Data in a but arranged such that each mouse is plotted as a single data point and grouped
by treatment with pre-immune huIgG, immune huIgG from a protected volunteer or immune huIgG from a non-protected volunteer. Above
each group is the mean % of PBS as well as asterisks indicating a signiﬁcant difference from the mean of pre-immune as measured by one-way
ANOVA with Kruskal–Wallis post-test. An additional Mann–Whitney test comparing the means of protected and non-protected is indicated by
bar and resulting p value. c Data represented as one mean per volunteer with Mann–Whitney test used to determine if the mean % of PBS
between mice receiving protected and non-protected huIgG are different. For all comparisons * is p< 0.05 and ** is p≤ 0.01
Fig. 7 The FRG huHep/Pf challenge model can be used to assess sterile protection. FRG huHep mice (n= 4–5 mice/group) were administered
indicated dose of mAb 2A10 or non-speciﬁc mIgG 1 day prior to challenge by bite of ﬁve PfNF54-infected mosquitos. On day 6.5, mice were iv-
injected with 400 μL of human red blood cells at 70% hematocrit. On day 7, peripheral blood was collected and used to assess presence of
parasitemia by qRT-PCR. a Copies/mL of parasite 18S rRNA for each indicated dose of mAb 2A10 with negative mice plotted on the x-axis.
Data points are individual mice with bars representing the mean± SEM for each group. As a negative qRT-PCR control, mIgG-treated mice
were bled prior to blood stage transition on day 6 (“150 μg mIgG D6”). Comparions between mIgG and 2A10-treated groups were carried out
by one-way ANOVA and Kruskall–Wallis post-test. Signiﬁcant differences are indicated by asterisk where p< 0.05. b Serum was collected
immediately prior to challenge and circulating levels of mAb 2A10 were measured by ELISA. Each data point is one mouse with bars
representing mean± SEM shown for each group and numerical mean above each data set
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with T cells also affords sterile protection in rodent malaria
models.49–51 However, the clinical performance of T cell based
malaria vaccines has been low.52–54
RTS,S partial efﬁcacy provided the impetus to embark on the
development of a second generation subunit vaccine that not
only boosts the quality, magnitude and durability of anti-CSP
antibodies, but also incorporates additional antibody targets
capable of blocking Pf sporozoite infection. However, these efforts
are encumbered by the lack of preclinical models for natural Pf
sporozoite infection delivered by mosquito bite. Here, we
optimized a regimen of Pf infection by mosquito bite in FRG
huHep mice that is consistent and robustly measures antibody
efﬁcacy with adequate group sizes over sequential experiments.
This challenge strategy also proved sensitive enough to noninva-
sively measure reductions in parasite liver stage burden following
passive transfer of mAbs in a manner that was at least as sensitive
as qRT-PCR of infected liver tissue. Our noninvasive biolumines-
cent readout was superior to a qRT-PCR method that avoids
processing the entire liver, but increased sensitivity might be
achieved if whole liver RNA preparation and qRT-PCR were
used.6,31,55 In addition, bioluminescent imaging is less time and
reagent intensive as demonstrated by the fact that the parasite
liver stage burden of 60 mice can be assessed in only
approximately 1.5 hours by a single experienced researcher.
The FRG huHep/Pf GFP_luc challenge model can thus be used
to down-select mAbs based on their in vivo function prior to
clinical advancement of either the mAb or targeted antigen.
Indeed, we were able to discriminate low-performing anti-CSP
mAbs such as clone 2A10 from those reducing parasite liver stage
burden by up to 90%. Importantly, antibody efﬁcacies were
maintained after switching to different mouse IgG subclasses or
human Fc. This is critical as mAb with human Fc (i.e., those isolated
from vaccinated volunteers) could set up a mismatch between the
human antibody and the FRG huHep mouse host. This mismatch
could obscure Fc-dependent antibody function given the poor
performance of human Fc regions in mice.38 While we did not see
an impact of the Fc region on Ab performance, we only tested
mAbs recognizing CSP, and previous reports have also shown that
the Fc region of anti-CSP antibodies is dispensable.44,56 Thus
testing of non-CSP speciﬁc antibodies could show different results
in the FRG huHep mouse if Fc-dependent mechanisms exist for
other antigen targets. One such antibody targeting the α-gal
glycan is heavily Fc-dependent in a rodent malaria model.57 As
similar antibodies become available for Pf, it will be important to
study their efﬁcacy in FRG huHep mice. Nevertheless, the FRG
huHep/Pf GFP_luc challenge model is sensitive, ﬂexible and
medium throughput, allowing for the functional activity screening
of both mAb and polyclonal IgG.
The in vivo efﬁcacy of antibodies against single antigens, such
as CSP, can also be tested in standard mice using transgenic
rodent malaria parasites where the endogenous antigen of
interest has been replaced by the Pf ortholog.16–18 However,
creation of these parasites is complex and the Pf protein must fully
complement the cognate rodent malaria parasite protein to yield
a viable parasite. This becomes increasingly difﬁcult if combina-
tions of antibodies targeting multiple proteins is desired as
parasites carrying all Pf proteins of interest must be made—
requiring multiple rounds of transgenesis and increasing the
likelihood of non-viable parasites. This approach is also not
suitable for use with polyclonal antibodies with unknown
speciﬁcities such as those derived from whole sporozoite
immunizations which might elicit thousands of different antigen
speciﬁcities.58 Polyclonal huIgG isolated from volunteers immu-
nized with whole sporozoites have been tested for the ability to
prevent liver stage infection in human liver-chimeric mice2,6,34 but
none of these studies rigorously investigated the range of huIgG
dose needed to determine protection nor have they investigated
antibody function in vivo as a correlate of protection. Here, we
determined that a wide range of polyclonal huIgG could be used
to observe antibody function and a dose of 16 mg/mouse is
needed to recapitulate levels of circulating huIgG found in human
serum. Knowing these requirements will help guide sampling
schedules in clinical trials where determining the function of
vaccine-elicited antibodies in vivo is desired.
We also investigated polyclonal huIgG activity elicited after
whole sporozoite immunization in vivo as a correlate of
protection. Using huIgG from volunteers 6 months after immuni-
zation with the irradiated PfSPZ vaccine, we found a weak
correlation between antibody function and protection of volun-
teers after CHMI. We observed a greater number of protected
volunteers whose huIgG mediated signiﬁcant inhibition of liver
stage infection in FRG huHep mice, but the correlation between
the ability of an individual’s huIgG to reduce liver stage burden
and protection was not signiﬁcant—largely due to a single
volunteer whose huIgG resulted, surprisingly, in an increased liver
stage burden. Thus, we could not establish a clear, predictive
correlate of protection in this study. This could be due to
limitations in antibody potency, the small sample size or the fact
that antibodies may play a minor role in protection in this
particular study. Immunization with irradiated sporozoites such as
PfSPZ has been shown in animal models to be heavily dependent
on liver-resident cytotoxic T cells,59,60 thus establishing a
dominant correlate of protection using only antibody function
might be unlikely. Still, our data add to the evidence that
vaccination with irradiated sporozoites induces long-lasting anti-
body responses capable of reducing the number of sporozoites
reaching the liver and is in agreement with previous research.2
In a further set of experiments using polyclonal huIgG from
volunteers immunized by CPS, we also observed a weak
correlation between in vivo huIgG function and protection from
CHMI despite less robust antibody function in individual
volunteers. Sample sizes were again small, but huIgG from
protected volunteers reduced parasite liver stage burden to a
greater degree than non-protected volunteers regardless of how
the data were analyzed. While conclusions regarding correlates of
protection in both of these trials should be tempered, it is clear
that we were able to detect differences in antibody function
between volunteers and between groups of distinct protection
status. This suggests that similar studies using larger clinical
cohort sizes could lead to the generation of statistically signiﬁcant
results and could be a critical tool for identifying correlates or
mechanisms of protection in multi-antigen or whole parasite
vaccination trials. Even if larger studies reveal no correlates of
protection with humoral immunity, knowing which arms of the
immune system mediate protection can help guide vaccine
design or delivery to best target that immune compartment.
Importantly, we also show that FRG-huHep mice can be used to
assess sterile protection when a highly sensitive Plasmodium 18 s
rRNA qRT-PCR assay is used to detect blood stage infection after a
lower, ﬁve mosquito bite challenge dose. This is the same
challenge dose used in CHMI trials and is the same diagnostic
endpoint assay used in such studies.19,34,42,43 All mock-treated
mice in our sterile protection experiment became blood stage
positive at day 7. Sterile protection is a binary readout with a
limited dynamic range. However, while sterile protection was
observed at the two highest doses of mAb 2A10 there was none in
the lowest dose group, suggesting that this model is still sensitive
to antibody dose and is reﬂective of overall efﬁcacy. When
coupled with the ability to modulate circulating mAb levels as
shown here, it will be possible to determine the concentrations of
antibody required to achieve sterile protection. This will be useful
for screening and down-selection of antibodies against novel
antigens or epitopes and the pre-CHMI determination of
protective levels of antibodies that ought to be achieved by
active immunization.
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Finally, a key ﬁnding across all of our experiments was that the
in vitro ISTI assay did not predict performance in the FRG huHep/
Pf GFP_luc challenge model. The mAbs we tested all performed
equally well in vitro yet exhibited large differences in reductions of
parasite liver stage burden in vivo. In vitro results for clinical
samples also did not predict any trends in inhibition and in fact
over-estimated antibody function in non-protected volunteers.
Thus, in vitro assays should be interpreted with caution and not
used in isolation for down-selection of antibodies/targets, nor
should they be used to rank antibody efﬁcacy. It is perhaps not
surprising that antibody function in vitro does not accurately
predict function in vivo as the sporozoite uses unique mechanisms
to travel through the dermis, into the circulation, across the liver
sinusoidal barrier and ﬁnally into the three-dimensional architec-
ture of the liver for liver stage development.9,10,33,35,47 All current
in vitro assays employ infection of hepatocytes in monoculture
which is not representative of the sporozoites’ complex journey to
the liver or the architecture of the target organ.26
FRG huHep mice still suffer some limitations for use in antibody
studies as they lack B, T, NK and NKT cells. This precludes the
detection of antibody efﬁcacy if it relies on interactions between
Fc regions and the Fc-receptors (FcR) on these cell types, although
to our knowledge, there is no demonstration of antibody function
against sporozoites being dependent on interacting with these
cell types. Nevertheless, FRG huHep mice do harbor antigen-
presenting cells such as dendritic cells and macrophages which
could phagocytose antibody-bound sporozoites.61 Polymorpho-
nuclear cells are also present in these mice62 and could augment
antibody-mediated prevention of liver infection.57 However, all
bone marrow-derived cells will contain mouse FcR that bind
poorly to human Fc regions and may limit the function of
transferred human mAb or huIgG.38 While the role of complement
in protection against sporozoite infection is unclear,44,56,57 it is also
unclear if these mice can ﬁx complement via the classical/
antibody-mediated pathway with either mouse or human
antibodies. FRG huHep mice do make human C3 (data not
shown), but it remains to be seen if this is functional in the
classical complement pathway.
Despite their limitations, our data show that FRG huHep mice
are a highly relevant laboratory model to study the role of
inhibitory antibodies against natural Pf infection. mAbs against
novel epitopes of existing antigen candidates or completely novel
candidates can be screened in FRG huHep mice and will thereby
help determine those that function best in vivo. The data can then
help guide rational structure-based antigen design as well as
down-select antigen candidates to move into CHMI trials using
either passive immunization with mAbs or active immunization
with the target antigen. Human liver-chimeric mice are also
suitable models to test the in vivo function of polyclonal
antibodies with diverse or unknown speciﬁcities such as those
derived from vaccination with complex immunogens, including
whole sporozoites. Testing of these antibodies in vivo will help
identify correlates or contributing mechanisms of protection that
cannot be discerned in vitro. Thus, the model described here can
further enable rational optimization of protective malaria vaccine
candidates and as such will form a bridge to clinical malaria
vaccine development efforts.
MATERIALS AND METHODS
FRG huHep mouse challenges
Human hepatocyte donor-matched FRG huHep mice (both male and
female, >4 months of age) were purchased from Yecuris, Inc. Repopulation
of human hepatocytes was conﬁrmed by serum albumin levels, and only
animals with serum albumin levels >3mg/mL were used. For passive
transfer, mice were intravenously or intraperitoneally injected with
indicated dose of anti-Pf CSP monoclonal antibody or huIgG 16–24 h prior
to challenge. mAbs were kindly provided by PATH Malaria Vaccine
Initiative where mAb1 is clone 3C1 and mAb2 is clone 2H8. For mosquito
bite challenge, Anopheles mosquitos infected with Pf expressing GFP-
luciferase or wild type NF54 were generated as previously described.36
Mosquito infection was quantiﬁed by midgut dissection at day 7–10 post-
blood meal and were used only if >50% of mosquitos contained an
average of >10 oocysts/midgut. All qualifying mosquitos were then pooled
and re-distributed into cages with ~50 mosquitos/mouse with up to 250
mosquitos. For ﬁve-mosquito bite challenge, the number of mosquitos/
mouse was adjusted to reﬂect infection prevalence (e.g., if 90% of
mosquitos were infected, a total of 28 mosquitos were added to a cage to
infect ﬁve mice). Mice, in groups of up to ﬁve, were then anesthetized with
isoﬂurane and placed on a mesh screen covering the container of
mosquitos while under isoﬂurane anesthesia via nose cone. Mosquitos
were then allowed to feed for 10min with lifting of mice every minute to
encourage probing and injection of sporozoites rather than blood feeding.
After 10min mice were returned to normal activity. At day 6 post infection
(peak of liver stage burden), mice were imaged for liver stage burden using
bioluminescence and IVIS imaging as previously described.33,63 Brieﬂy,
mice were intraperitoneally injected with 100 μL of Rediject D-luciferin
(Perkin Elmer) and imaged after 5 min for a ﬁve-minute exposure. Liver
stage burden was assessed by placing an identical region of interest
around the liver of each mouse and measuring total ﬂux in pixels/second
(p/s). Liver stage burden of all mice was normalized by setting the mean of
the negative control group that received non-speciﬁc, species-matched
IgG or pre-immune huIgG to 100% within each bite experiment. Liver stage
burden was alternatively assessed in a subset of experiments by
Plasmodium 18S rRNA RT-PCR normalized to hApoA1 mRNA, as previously
reported.6,64
For assessment of sterile protection, mice were iv-injected with 400 μL of
human red blood cells at 70% hematocrit in RPMI 6.5 days post challenge.
On day 7, mice were bled via the retroorbital plexus and exactly 50 μL of
blood was placed into 1 mL of Nuclisens EasyMag buffer (bioMérieux) and
stored at −80 °C until extraction. Total RNA was extracted using an
EasyMag instrument (bioMérieux) as described.43 Plasmodium 18S rRNA
qRT-PCR was performed as described65 although newly described pan-
Plasmodium 18S rRNA-speciﬁc reagents were used herein.66 Mice were
considered positive if qRT-PCR was above the undetectable qRT-PCR signal
obtained on day 6 post challenge.
ELISA for serum mAb concentration
Mice were bled via retroorbital plexus immediately prior to challenge and
blood allowed to clot in BD serum separator tubes for 2 h. Serum was
separated by centrifugation at 14,000×g for 2 min. For ELISA, Costar
EasyWash (Corning) were coated with 2 μg/mL in coating buffer as
previously described.34 Plates were then blocked with dilution/blocking
buffer (0.05% Tween-20, 6% bovine serum albumin in PBS) for 1 h at room
temperature. After washing, 50 μL of serum samples were applied in
duplicate at 1:160 and 1:320 dilutions in dilution/blocking buffer. A
standard curve was generated using eight two-fold dilutions of
2A10 starting at 625 ng/mL in dilution/blocking buffer and 50 μL applied
in duplicate with samples. Standards and serum samples were incubated
at room temperature for 2 h. After washing, HRP-conjugated anti-mouse
IgG was applied at a 1:5000 dilution for 1 h at room temperature. Plates
were developed with SureBlue™ TMB reagent for 4 min and stopped with
SureBlue™ Stop reagent before reading absorbance at 450 nm. Serum
concentrations were interpolated using a 4-parameter non-linear regres-
sion of the standard curve.
Ethics statement
All animal procedures were conducted in accordance with and approved
by the Center for Infectious Disease Research Institutional Animal Care and
Use Committee (IACUC) under protocol SK-16. The Seattle Biomed IACUC
adheres to the NIH Ofﬁce of Laboratory Animal Welfare standards (OLAW
welfare assurance # A3640-01).
Preparation of monoclonal and polyclonal antibodies
Monoclonal antibody 1 (mAb 1, clone 3C1) was prepared as previously
described.2 Monoclonal antibody 2 (mAb 2, clone 2H8) was generated
under a Gennova-PATH Malaria Vaccine Initiative collaborative program by
immunization of mice against full length PfCSP produced by Gennova.
Hybridoma clone 2A10 speciﬁc for Pf CSP was obtained from MR4 and
ProMab Biotechnologies, Inc. performed antibody production and
puriﬁcation. For IgG isolated from human serum, samples were prepared
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as recently published.2 Brieﬂy, serum was used for extraction of IgG using
protein G columns (GE Healthcare Life Sciences) following manufacturer’s
protocol and concentrated using Amicon Ultra-15 centrifugal units (EMD
Millipore) to 20–25mg/mL in PBS.
In vitro inhibition of sporozoite invasion and traversal assay (ISTI)
Antibodies and IgG were tested at indicated concentrations in ISTI
following previously published methods.67,68 Brieﬂy, freshly dissected Pf
sporozoites were incubated with antibodies at indicated concentrations in
DMEM media containing 10% heat-inactivated FBS supplemented with
glutamine, penicillin/streptomycin, Fungizone and FITC-dextran for 15min
a 37 °C. Sporozoites and media were then added to HC04 cells (ATCC, Inc.)
plated 1 day prior at 105 cells/well in a 96-well plate at an MOI of 0.3
(sporozoites:HC04 cells). Plates were then spun at 500×g for 3 min and
incubated for 90min at 37 °C. Cells were then washed, trypsinized and
transferred to a new 96-well plate where they were ﬁxed and
permeabilized using BD cytoﬁx/cytoperm (BD Biosciences). Cells were
then stained with anti-CSP mAb conjugated to AlexaFluor-647 and
analyzed by ﬂow cytometry using a BD LSRII and FloJo analysis software.
Cells were considered “invaded” if they were CSP-positive and “traversed”
if they had taken up FITC-dextran due to cell membrane wounding.
Antibody-treated wells were normalized to either species-matched non-
speciﬁc IgG for mAbs and to pooled pre-immune IgG at equivalent
concentrations. Anti-CSP mAb 2A10 was included at 10 μg/mL in each
assay as a positive control for inhibition.
Statistical analysis
Relevant statistical tests are indicated in ﬁgure legends and were conducted
using GraphPad Prism 6.0 for Mac. Signiﬁcant results are indicated in ﬁgures
with relevant p values indicated by “*” in each ﬁgure legend. Comparisons
not indicated in ﬁgures were non-signiﬁcant with p > 0.05.
Data availability
The data that support the ﬁndings of this study are available from the
corresponding author upon reasonable request.
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